Kronos Bio

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Kronos Bio and other ETFs, options, and stocks.

About KRON

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers.

CEO

Norbert W. Bischofberger

CEONorbert W. Bischofberger

Employees

Employees96

Headquarters

San Mateo, California

HeadquartersSan Mateo, California

Founded

2017

Founded2017

Employees

Employees96

KRON Key Statistics

Market cap

181.66M

Market cap181.66M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

174.65K

Average volume174.65K

High today

$3.27

High today$3.27

Low today

$3.18

Low today$3.18

Open price

$3.20

Open price$3.20

Volume

116.00K

Volume116.00K

52 Week high

$20.97

52 Week high$20.97

52 Week low

$2.96

52 Week low$2.96

Analyst ratings

100%

of 6 ratings

Buy

100%

Hold

Sell

KRON Earnings

-$1.13

-$0.75

-$0.38

$0.00

Q1 FY21

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Nov 3, After Hours

ActualExpected Nov 3, After Hours

Kronos Bio

Why Robinhood?

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers. Show more

KRON Key Statistics

Analyst ratings

100%

Kronos Bio, Inc. is a clinical-stage biopharmaceutical, engages in the provision of discovery and development of novel cancer therapeutics products. Its pipeline includes hematologic malignancies, prostate cancer, MYC-driven cancers, and small cell/neuroendocrine cancers.